Low-Dose Methotrexate and Bone Health: Pathophysiological and Clinical Perspectives
Abstract
This narrative review summarizes current evidence on the molecular and cellular effects of low-dose methotrexate (LD-MTX) on bone tissue. In addition, it critically examines the limited and heterogeneous data on LD-MTX-associated osteopathy, a rare and incompletely understood condition that may be underrecognized in clinical practice. Finally, the review highlights key knowledge gaps and outlines future research directions aimed at improving diagnosis, management, and prevention. In total, 451 relevant articles were retrieved, and 71 studies were included in our review. Methotrexate (MTX) has been shown to prevent bone loss associated with inflammatory rheumatic diseases, primarily through its anti-inflammatory properties. However, current evidence highlights a variety of negative effects on bone associated with LD-MTX therapy, including osteoblast dysfunction, increased osteoclastogenesis, and endothelial damage. Collectively, these effects may result in deterioration of microarchitecture, impaired bone healing and insufficiency fractures. Despite the long and successful use of MTX in rheumatology, our knowledge of its effects on bone and awareness of LD-MTX osteopathy remain limited, potentially leading to delayed or missed diagnoses. Recent clinical studies highlight the potential underestimation of this condition and emphasize the need for further research to establish clear diagnostic criteria and treatment guidelines, as well as to achieve a more comprehensive…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.